ACOG
NASDAQ HealthcareAlpha Cognition Inc. - Common Stock
Biotechnology
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
�� 市场数据
| 价格 | $8.84 |
|---|---|
| 成交量 | 366,866 |
| 市值 | 192.48M |
| RSI（14日） | 53.6 |
| 200日均线 | $6.36 |
| 50日均线 | $7.68 |
| 52周最高 | $10.00 |
| 52周最低 | $4.50 |
| Forward P/E | -14.79 |
| Price / Book | 3.08 |
🎯 投资策略评分
ACOG 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (45/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ACOG in your text
粘贴任何文章、记录或帖子 — 工具将提取 ACOG 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-08-17.